| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Novartis Pharma AG, Basel, Switzerland
Correspondence: Correspondence: Jonathan R. Green, Ph.D., Novartis Pharma AG, Klybeckstrasse 141, WKL-125.901, CH-4002 Basel, Switzerland. Telephone: 41-61-696-4415; Fax: 41-61-696-3849; e-mail: jonathan.green{at}pharma.novartis.com
Bisphosphonates effectively inhibit osteoclast-mediated bone resorption and are integral in the treatment of benign and malignant bone diseases. The evolution of bisphosphonates over the past 30 years has led to the development of nitrogen-containing bisphosphonates (N-BPs), which have a mechanism of action different from that of the nonnitrogen-containing bisphosphonates. Studies conducted over the past decade have elucidated the mechanism of action and pharmacologic properties of the N-BPs. N-BPs exert their effects on osteoclasts and tumor cells by inhibiting a key enzyme in the mevalonate pathway, farnesyl diphosphate synthase, thus preventing protein prenylation and activation of intracellular signaling proteins such as Ras. Recent evidence suggests that N-BPs also induce production of a unique adenosine triphosphate analogue (Apppi) that can directly induce apoptosis. Our increased understanding of the pharmacologic effects of bisphosphonates is shedding light on the mechanisms by which they exert antitumor effects. As a result of their biochemical effects on protein prenylation, N-BPs induce caspase-dependent apoptosis, inhibit matrix metalloproteinase activity, and downregulate
vß3 and vß5 integrins. In addition, zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp.; East Hanover, NJ and Basel, Switzerland) exerts synergistic antitumor activity when combined with other anticancer agents. Zoledronic acid also inhibits tumor cell adhesion to the extracellular matrix and invasion through MatrigelTM and has antiangiogenic activity. A growing body of evidence from animal models demonstrates that zoledronic acid and other bisphosphonates can reduce skeletal tumor burden and prevent metastasis to bone. Further studies are needed to fully elucidate these biochemical mechanisms and to determine if the antitumor potential of bisphosphonates translates to the clinical setting.
This article has been cited by other articles:
 |
|
 |
|
  M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lipton, R. J. Cook, P. Major, M. R. Smith, and R. E. Coleman Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity Oncologist, September 1, 2007; 12(9): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Mason, M. R. Sydes, J. Glaholm, R. E. Langley, R. A. Huddart, M. Sokal, M. Stott, A. C. Robinson, N. D. James, M. K. B. Parmar, et al. Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873) J Natl Cancer Inst, May 16, 2007; 99(10): 765 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Scotte, J.-M. Tourani, E. Banu, M. Peyromaure, E. Levy, S. Marsan, E. Magherini, E. Fabre-Guillevin, J.-M. Andrieu, and S. Oudard Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand J. Clin. Oncol., July 1, 2005; 23(19): 4424 - 4429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Conte Optimizing Bisphosphonate Therapy in Oncology Oncologist, September 1, 2004; 9(suppl_4): 1 - 2. [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
